Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes

BJU International

Volumn 110, Issue 11, 2012, Pages 1702-1707

  Pfeiffer, Dietrich ^a   Berger, Jürgen ^a   Gross, Andreas J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

efficacy; HIFU; high intensity focused ultrasonography; morbidity; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER CONTROL; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOMECTOMY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; RETROSPECTIVE STUDY; SURVIVAL RATE; TRANSURETHRAL RESECTION;

EID: 84870952367     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11375.x     Document Type: Article

References (30)

1. Shao Y, Albertsen PC, Roberts CB, et al,. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med 2010; 170: 1256-61
2. Cooperberg MR, Broering JM, Carroll PC,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
3. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M,. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55: 3346-51
4. Gelet A, Chapelon JY, Bouvier R, et al,. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996; 29: 174-83
5. Thüroff S, Chaussy C, Vallancien G, et al,. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multcentric study. J Endourol 2003; 17: 673-77
6. Blana A, Murat FJ, Walter B, et al,. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008; 53: 1194-203
7. Crouzet S, Rebillard X, Chevallier D, et al,. Multicentric oncological outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 2010; 58: 559-66
8. Chaussy C, Thüroff S,. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003; 4: 248-52
9. Chaussy CG, Thuroff SF,. Robotic high-intensity focused ultrasound for prostate cancer: what have we learned in 15 years of clinical use? Curr Urol Rep 2010; 12: 180-87
10. Blana A, Brown SC, Chaussy C, et al,. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009; 104: 1058-62
11. Patel A, Dorey F, Franklin J, deKernion JB,. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling time and log slope prostate specific antigen. J Urol 1997; 158: 1441-45
12. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
13. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-34
14. Ganzer R, Paulescu A, Berge V, et al,. 10 Year outcome and morbidity of high-intensity focused ultrasound (HIFU) as a primary therapy for localized prostate cancer: outcomes from 2552 men followed with the @-registry. J Urol 2011; 185 (Suppl. 4): 404
15. Ganzer R, Robertson CN, Ward JF, et al,. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria-analysis from the @-registry. BJU Int 2011; 108: 196-201
16. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A,. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 2007; 110: 68-80
17. Roach M 3rd, Hanks G, Thames H Jr, et al,. Defining biochemical failure following radiation therapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendation of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74
18. Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Orovan WL,. 2 years biochemical failure free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: prospective cohort single center study of 196 patients. J Urol 2009; 181 (Suppl. 4): 714
19. Hoppmann PR, van Randenborgh H, Kübler H, Alschibaja M, Günther M, Hartung R,. Residual benign prostatic glands at the urethravesical anastomosis after radical retropubic prostatectomy: prediction and impact on disease outcome. Eur Urol 2004; 46: 321-26
20. Rebillard X, Soulie M, Chartier-Kastler E, et al,. High-intensity-focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008; 101: 1205-13
21. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B,. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006; 24: 585-90
22. Netsch C, Bach T, Gross E, Gross AJ,. Rectourethral fistula after high-intensity focused ultrasound therapy for prostate cancer and its surgical management. Urology 2011; 77: 999-1004
23. Heidenreich A, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
24. Dearnaley DP, Sydes MR, Graham JD, et al,. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87
25. Goldner G, Dimopoulos J, Kirisits C, Pötter R,. Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy. Strahlenther Onkol 2009; 7: 438-45
26. Wong WW, Vora SA, Schild SE, et al,. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 2009; 115: 5596-606
27. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A,. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008; 179: 1368-73
28. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-19
29. Thaxton CS, Loeb S, Roehl KA, Kan D, Catalona WJ,. Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology 2010; 75: 414-18
30. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR,. CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008; 180: 1330-34